ORAFURAN
| StockNo |
Product description |
Status |
| EB0280-408-10 |
ORAFURAN
TABL 100 MG X 50 |
 |
-
- COMPOSITION:
Nitrofurantoin 100 mg in one tablet
ACTION:
It is a nitrofuran derivative with selective chemotherapeutic action
against infectious of the urinary canals. Its antimicrobial; action
covers Gram-positive bacteria (enterococci, staphylococci,
streptococci) and Gram-negative bacteria, above all the causative
agents of urologic infections (Escherichia coli, Enterobacter
aerogenes, some strains of Proteus); it is also active against
Shigella, Salmonella, Clostridium perfringens. The agent has a light
or no action against Proteus vulgaris and Pseudomonas aeruginosa. It
has no effect on fungi and viruses. The microorganisms develop a
slow resistance but when developed it can be strong. It has an
effect on pathogenic bacteria resistant to sulfonamides and
antibiotics. It is well absorbed and is quickly eliminated through
the kidneys. In acid urine it has a bacterial effect against the
majority of microorganisms (with the exception of Ps. aeruginosa).
INDICATIONS:
Infections of urinary ducts: cystitis, pyelitis, urethritis,
prostatitis, pyelonephritis; chronic recurrent infections of the
urinary ducts induced by microorganisms resistant to sulfonamides
and antibiotics; for prophylaxis in urological surgery, cystoscopy,
catherization, etc.
CONTRAINDICATIONS:
Severe damage of the kidneys as a toxic effect is likely to occur
when the elimination of the agent is impeded.
SIDE EFFECTS:
It can induce loss of appetite in some cases, as well as nausea,
pyrosis, vomiting. Allergic reactions are also possible. To avoid
all those adverse effects the agent should be taken with large
quantities of liquids. The urine is sometimes colored brown during
the treatment wit the drug. |
DRUG INTERACTIONS:
The absorption of orafuran is inhibited and its antibacterial action
is diminished after simultaneous administration with nalidixic acid.
The substances acidifying the urine enhance the antibacterial
activity of orafuran (reduce its excretion) whereas the alkalizing
agents reduce its activity by impending its reabsorption with
akcohol, uraforan can inhibit acetaldehyde oxidation and induce a
disulfiram-like reaction. The anticholinergic agent can increase the
biological availability of orafuran by reducing the gastrointestinal
motility.
DOSAGE AND ADMINISTRATION:
Orally - 5-8 mg/kg daily. It is usually prescribed as one tablet,
3-4 times daily during meals with sufficient quantity of liquids.
The treatment lasts for 5-8 days. In the absence of an effect during
that period the treatment is stopped. The treatment course should
not be longer than 14 successive days. Subsequent courses should be
prescribed at intervals of 4 weeks. In some diseases (epididymitis,
prostatitis) the drug is prescribed together with antibiotics.
PRECAUTIONS:
In pronounced adverse effects and allergic skin reactions the
administration of the drug must be discontinued. Due to available
data on its neurotoxic action - peripheral, symmetric and motor
polyneuritis, the agent should be administered very cautiously,
particularly when long-term treatment is needed. In such cases the
patient must be followed up for the occurrence of paresthesia as an
early symptom. The patients with azotemia are particularly at risk.
MEDICINAL FORM AND PACKAGE:
Packages with 50 tablets of 100 mg.
STORAGE:
In a place protected from light, at moderate temperature (15-30°
C).
EXPIRY:
5 (five) years.
|
